Premera Blue Cross and Express Scripts Agree to Contract Extension
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Tesla acquires AI hardware company for up to $2 billion in stock
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
Express Scripts (ESRX), Imprimis Pharma (IMMY) to Partner on Low-Cost Alternative to Turing's Daraprim
December 1, 2015 6:24 AM ESTExpress Scripts (Nasdaq: ESRX) announced it will partner with Imprimis Pharmaceuticals (Nasdaq: IMMY) to drive access to a low-cost alternative to Daraprim (pyrimethamine), a drug for the treatment of toxoplasmosis that has been recently priced out of reach for people with HIV, pregnant women and others with weakened immune systems.
Imprimis is offering a compounded oral formulation of pyrimethamine and leucovorin (a form of folic acid) for $1 per capsule for people whose pharmacy benefit is managed by Express Scripts. While the 62-year-old Daraprim was priced $13.50 per pill... More
